CommercialPrior AuthMedium impact
08.01.66e, Cemiplimab-rwlc (Libtayo®)
Independence Blue Cross·Oncology, Dermatology·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
The policy for Cemiplimab-rwlc (Libtayo®), a cancer immunotherapy drug, has been updated with changes to medical necessity criteria, medical coding requirements, and general guidelines. This affects how the medication is covered and billed under commercial insurance plans.
Action Required
By December 29, 2025: Billing team must review the updated Cemiplimab-rwlc (Libtayo®) policy at the provided URL to understand new medical necessity criteria and coding requirements. Update prior authorization procedures and documentation requirements for this cancer immunotherapy drug. Ensure providers are aware of any new coverage criteria before prescribing.